CD4 and cancer: Methods: ART‐naïve PWH in the Icona Foundation Cohort with CD4 count <200 cells/mm3 and/or AIDS diagnosis (excluding cancers, cryptococcosis, tuberculosis and other mycobacterial infection), who started a first‐line three‐drug regimen with DTG or DRV/b over the period 2014–2023 were included.